Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,738 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Failure Chronic Clear all
Completed Not applicable Interventional Results available

Sodium Thiosulfate Treatment of Vascular Calcification in ESRD

NCT00568399
View directory record Official record
Conditions
Complication of Hemodialysis, Cardiovascular Diseases
Interventions
sodium thiosulfate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis

NCT04571619
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Pain, Opioid Dependence
Interventions
Pain Coping Skills Training (PCST), Buprenorphine
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
West Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 22, 2026, 11:22 AM EDT
Withdrawn No phase listed Observational

Serum Potassium Prediction Using Machine Learning and Single-lead ECG

NCT07493798
View directory record Official record
Conditions
Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Potassium estimation algorithm
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Terminated No phase listed Observational

Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis

NCT00883636
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Chronic Kidney Disease
Interventions
Cardiovascular Assessment, Renal Assessment, Genetic Evaluation
Other
Lead sponsor
Northwell Health
Other
Eligibility
6 Months to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease

NCT04072432
View directory record Official record
Conditions
Healthy Volunteers, Chronic Kidney Disease
Interventions
RBT-3
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Edgewater, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Not applicable Interventional Results available

Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease

NCT01012089
View directory record Official record
Conditions
Chronic Kidney Disease, Bacterial Infection
Interventions
Daptomycin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment

NCT04849650
View directory record Official record
Conditions
Renal Disease, End Stage
Interventions
Amisulpride IV, Amisulpride Oral Tablet
Drug
Lead sponsor
Acacia Pharma Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Not applicable Interventional

End-Stage Renal Disease Intra-dialysis Lifestyle Education Study

NCT02361268
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Intradialysis-yoga, Educational program
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Analysis of Calcium Balance in Chronic Kidney Disease

NCT00974532
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
High calcium diet 2000 mg/day, Low calcium diet, 800 mg/day
Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis

NCT02335099
View directory record Official record
Conditions
End Stage Renal Disease, Vascular Access Patency
Interventions
ticagrelor, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 22, 2026, 11:22 AM EDT
Not yet recruiting No phase listed Observational

Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function

NCT07645599
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent, DEFINITY®
Diagnostic Test · Drug
Lead sponsor
Roderick Tan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.

NCT00752609
View directory record Official record
Conditions
Anemia
Interventions
Peginesatide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 22, 2026, 11:22 AM EDT
Recruiting Phase 2Phase 3 Interventional

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
CSL300, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
3,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
166
States / cities
Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 121 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Completed No phase listed Observational

Risk of Chronic Kidney Disease Progression

NCT02654756
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease
Interventions
Not listed
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation

NCT02586051
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Obinutuzumab, Intravenous Immunoglobulin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 22, 2026, 11:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

Breakthrough - T1DM and Chronic Kidney Disease

NCT07592000
View directory record Official record
Conditions
Diabete Type 1, Chronic Kidney Disease
Interventions
Tegoprubart, Islet Cell Transplant
Drug · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Miami, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Terminated Phase 2 Interventional

A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis

NCT00381602
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
GHRP-1/AG 70 mg depot in ESRD, Placebo
Drug · Other
Lead sponsor
QLT Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
New Orleans, Louisiana • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Oct 22, 2026, 11:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation

NCT07287800
View directory record Official record
Conditions
Hypogonadism, Male, End Stage Renal Disease (ESRD), Kidney Transplant
Interventions
Testosterone Replacement Therapy
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Not applicable Interventional Results available

Comparative Effects Of Dialysate Flow Rate And Membrane Packing On The Performance Of Dialyzers Used For Hemodialysis

NCT00636077
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Renal Disease
Interventions
Polyflux HD-C4 Big, HD-C4 Small, Optiflux 160NR, Optiflux 200NR
Device
Lead sponsor
Vantive Health LLC
Industry
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 22, 2026, 11:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Network Analysis of Urinary Molecular Signature Complements Clinical Data to Predict Postoperative Acute Kidney Injury

NCT02114138
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
pathogenesis of perioperative acute kidney injury, urine collection
Procedure · Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01906489
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease
Interventions
AKB-6548, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 82 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome

NCT03452189
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Vancomycin, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 22, 2026, 11:22 AM EDT
Enrolling by invitation Not applicable Interventional

Expanding and Promoting Alternative Care and kNowledge in Decision-making Trial

NCT06243068
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Educate and Engage, Educate and Engage Plus Kidney Supportive Care Program
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
65 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
25
States / cities
San Francisco, California • Washington D.C., District of Columbia • Canton, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 22, 2026, 11:22 AM EDT